GFPrint and PredLung nominated finalists in the AstraZeneca’s BeLung Innovation challenge

Two machine learning frameworks developed in Topazium, GFPrint™ and PredLung™, have been used to extract important information from cancer patients, in particular from lung cancer patients, that may serve to design better therapies, generate virtual biomarker signatures and predict patient outcomes. Three case studies are presented, focused on i) the discovery of potential novel targets…

GFPrint™: a machine learning tool for transforming genetic data into clinical insights

The increasing availability of massive genetic sequencing data in the clinical setting has triggered the need for appropriate tools to help fully exploit the wealth of information these data possess. GFPrint™ is a proprietary streaming algorithm designed to meet that need. By extracting the most relevant functional features, GFPrint™ transforms high-dimensional, noisy genetic sequencing data…

Topazium Receives the 2023 Artificial Intelligence and Advanced Technologies Award from the Madrid City Council for HealthGuard™

Madrid, February 21, 2024. Topazium, a company specializing in the application of artificial intelligence in the field of biomedicine, has been awarded the 2023 Artificial Intelligence and Advanced Technologies Award by the Madrid City Council for HealthGuard™, a machine learning framework designed and developed by the company that utilizes the most advanced AI technologies to…